Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Precision cancer vaccines to prevent metastatic recurrence
Infinitopes is a clinical-stage biotechnology company developing therapeutic cancer vaccines designed to prevent metastatic recurrence. Its lead candidate ITOP1 is a precision viral vector cancer vaccine targeting tumour antigens in patients with surgically resectable oesophageal adenocarcinoma, to be administered in…
TYK2/JAK1 inhibitor advancing towards Phase 2 psoriasis trials
Sareum is a clinical-stage biotechnology company developing small-molecule kinase inhibitors for autoimmune diseases and cancer. Its lead oral TYK2/JAK1 inhibitor, SDC-1801, completed Phase 1 testing in healthy volunteers and is being prepared for a Phase 2 study in psoriasis. Dosing in its Phase 2-enabling toxicology…
Preclinical CRO for receptor pharmacology and occupancy studies
Gifford Bioscience is a contract research organisation providing receptor pharmacology and occupancy services for preclinical and discovery stage drug development. The company conducts radioligand binding assays, functional GPCR assays, receptor occupancy studies, autoradiography, and surface plasmon resonance using…
AI platform predicting patient response to cancer immunotherapy
Curenetics is a medical technology company developing AI-powered tools to predict cancer patient responses to immunotherapy before treatment begins. Its platform integrates multi-omic genomic data, imaging profiles and clinical information to identify biomarkers of treatment efficacy and toxicity. The company also…
Full-service contract research organisation for clinical trials
Worldwide Clinical Trials is a global contract research organisation providing clinical development services to pharmaceutical and biotechnology companies. It supports studies from early to late phase, including clinical operations, biostatistics, data management, medical writing, regulatory affairs and…
Blood-based microRNA test for multi-cancer early detection
Xgenera is a diagnostics company developing a blood test for the early detection of multiple cancers from a single sample. The test measures circulating microRNA biomarkers using PCR-based methods and applies machine learning to identify signals from up to 12 common cancers before symptoms appear. The company is…
Off-the-shelf Natural Killer cell therapies for solid and blood cancers
NK:IO develops cancer immunotherapies based on human Natural Killer cells, harnessing the body's innate immune system as an alternative to T-cell-based approaches. The company's patented platform activates cord blood-derived stem cells to produce NK cells at high potency and yield, addressing manufacturing challenges…
Oncolytic adenovirus therapeutics for solid tumour cancer treatment
PsiVac is a UK-based biotechnology company developing oncolytic virus therapeutics for the treatment of cancer. Its patented technology uses genetically modified adenoviruses engineered to selectively replicate within and destroy tumour cells while leaving healthy cells intact, while also stimulating the body's immune…
Breath-based molecular liquid biopsies for early lung cancer detection
Respiro Diagnostics is a biotechnology company developing non-invasive molecular diagnostics for respiratory diseases, initially focusing on lung cancer. Its investigational platform collects exhaled breath samples and analyses lung-derived molecular biomarkers, including nucleic acids and proteins, to support earlier…
Small molecule MMR inhibitors to enhance tumour immunogenicity
NeoPhore is a UK immuno-oncology company developing first-in-class small molecule inhibitors of the DNA mismatch repair pathway. By transiently blocking MMR, the company's compounds render tumours MMR-deficient and immunogenic, generating neoantigens that stimulate immune responses against cancer. The approach aims to…
European specialty pharma focused on gastroenterology and hepatology
Norgine is a European specialty pharmaceutical company developing, manufacturing, and commercialising medicines across gastroenterology, hepatology, and cancer supportive care. Founded in 1906 and privately owned, the company markets a portfolio of specialty pharmaceutical products and medical devices across Europe,…
Liquid biopsy NGS kits and genomic diagnostic services
Nonacus is a developer of next-generation sequencing reagents and library preparation kits for liquid biopsy and tissue-based genomic analysis. Its target enrichment and cell-free DNA workflow products support cancer detection, treatment stratification, and longitudinal monitoring. Through its clinical services…
Global licensing and commercialisation of established branded pharmaceutical medicines
Pharmanovia is a specialty pharmaceutical company that acquires, licenses and commercialises established branded medicines, extending their lifecycle for patients worldwide. The company's portfolio spans more than 25 medicines across endocrinology, neurology, cardiovascular and oncology, built through strategic…
AI-powered bioinformatics platform for precision oncology and drug discovery
Rayca Precision develops AI and bioinformatics platforms for precision oncology and drug discovery, using transcriptomic data and deep learning to predict drug responses and stratify cancer patients. The company also provides automated multi-omics analysis for preclinical and clinical research workflows, and works…
Clinical-stage biopharma improving nucleoside analogue chemotherapy efficacy
NuCana is a clinical-stage biopharmaceutical company developing a pipeline of cancer medicines using proprietary phosphoramidate prodrug chemistry. Its approach transforms established nucleoside analogue chemotherapy agents into modified forms that bypass key tumour resistance mechanisms, delivering higher…
AI-guided personalised mRNA cancer vaccine development
Genevation is a biotechnology company developing personalised mRNA cancer vaccines using AI-assisted tumour neoantigen identification. Its platform analyses tumour sequencing data to select patient-specific targets and combines computational vaccine design with cell-free RNA manufacturing. The company reports…
Carbohydrate binding molecules targeting the tumour glycome in cancer
Omideon is a Scottish preclinical biotechnology company applying multivalent carbohydrate binding molecule (mCBM) technology to oncology. Spun out from Pneumagen Limited by demerger in 2020, the company uses genetic engineering to develop mCBMs with high affinity for tumour-associated terminal glycans. Its lead…
Infrared spectroscopy blood test for early multi-cancer detection
Dxcover is a clinical-stage biotechnology company developing a blood-based multi-cancer early detection test. Its platform applies infrared spectroscopy to a dried blood spot to capture a pan-omic biological signature spanning proteins, lipids, metabolites, and nucleic acids simultaneously. Machine learning algorithms…
Next-generation lipid nanoparticle platform for RNA vaccines and medicines
NeoVac is a biotechnology company developing a next-generation lipid nanoparticle platform to improve the delivery of RNA vaccines and therapeutics. Its library of fully biodegradable, tissue-targeted LNPs addresses limitations of first-generation formulations, offering enhanced thermostability, multiple routes of…
GPR35 inhibitors for gastrointestinal cancer and inflammatory bowel disease
ThirtyFiveBio is a drug discovery company developing first-in-class small molecule inhibitors of GPR35, a genetically validated G protein-coupled receptor implicated in gastrointestinal disease. The company's approach targets GPR35 antagonism to prevent epithelial cell damage and dysfunction in the gut wall,…